ABSTRACT
INTRODUCTION: Timely descriptions of HIV service characteristics and their evolution over time across diverse settings are important for monitoring the scale-up of evidence-based program strategies, understanding the implementation landscape, and examining service delivery factors that influence HIV care outcomes. METHODS: The International epidemiology Databases to Evaluate AIDS (IeDEA) consortium undertakes periodic cross-sectional surveys on service availability and care at participating HIV treatment sites to characterize trends and inform the scientific agenda for HIV care and implementation science communities. IeDEA's 2020 general site assessment survey was developed through a consultative, 18-month process that engaged diverse researchers in identifying content from previous surveys that should be retained for longitudinal analyses and in developing expanded and new content to address gaps in the literature. An iterative review process was undertaken to standardize the format of new survey questions and align them with best practices in survey design and measurement and lessons learned through prior IeDEA site assessment surveys. RESULTS: The survey questionnaire developed through this process included eight content domains covered in prior surveys (patient population, staffing and community linkages, HIV testing and diagnosis, new patient care, treatment monitoring and retention, routine HIV care and screening, pharmacy, record-keeping and patient tracing), along with expanded content related to antiretroviral therapy (differentiated service delivery and roll-out of dolutegravir-based regimens); mental health and substance use disorders; care for pregnant/postpartum women and HIV-exposed infants; tuberculosis preventive therapy; and pediatric/adolescent tuberculosis care; and new content related to Kaposi's sarcoma diagnostics, the impact of COVID-19 on service delivery, and structural barriers to HIV care. The survey was distributed to 238 HIV treatment sites in late 2020, with a 95% response rate. CONCLUSION: IeDEA's approach for site survey development has broad relevance for HIV research networks and other priority health conditions.
Subject(s)
Acquired Immunodeficiency Syndrome , COVID-19 , HIV Infections , Tuberculosis , Pregnancy , Adolescent , Humans , Female , Child , Acquired Immunodeficiency Syndrome/diagnosis , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/epidemiology , Cross-Sectional Studies , COVID-19/epidemiology , HIV Infections/diagnosis , HIV Infections/drug therapy , HIV Infections/epidemiology , Surveys and QuestionnairesABSTRACT
Paul De Lay and co-authors introduce a Collection on the design of targets for ending the AIDS epidemic.
Subject(s)
Acquired Immunodeficiency Syndrome/prevention & control , Disease Eradication/trends , Global Health/trends , Public Health/trends , Acquired Immunodeficiency Syndrome/diagnosis , Acquired Immunodeficiency Syndrome/economics , Acquired Immunodeficiency Syndrome/epidemiology , Disease Eradication/economics , Forecasting , Global Health/economics , Health Care Costs/trends , Humans , Public Health/economics , Time Factors , United NationsABSTRACT
Driven by a mission of justice, Manhattan Plaza and Penn South create beloved communities that care for people at all stages of life.
Subject(s)
Acquired Immunodeficiency Syndrome/therapy , Coronavirus Infections/epidemiology , Housing/organization & administration , Independent Living/statistics & numerical data , Pandemics/statistics & numerical data , Pneumonia, Viral/epidemiology , Social Welfare/economics , Acquired Immunodeficiency Syndrome/diagnosis , Acquired Immunodeficiency Syndrome/epidemiology , Aged , COVID-19 , Female , Geriatric Assessment , Humans , Male , Narration , New York City , Quality of Life , Social Welfare/statistics & numerical data , Socioeconomic FactorsSubject(s)
Acquired Immunodeficiency Syndrome/epidemiology , Coronavirus Infections/epidemiology , Malaria/epidemiology , Pneumonia, Viral/epidemiology , Tuberculosis/epidemiology , Acquired Immunodeficiency Syndrome/diagnosis , Acquired Immunodeficiency Syndrome/drug therapy , COVID-19 , Humans , Malaria/diagnosis , Malaria/drug therapy , Pandemics , Tuberculosis/diagnosis , Tuberculosis/drug therapyABSTRACT
Viral infectious diseases have resulted in millions of deaths throughout history and have created a significant public healthcare burden. Tremendous efforts have been placed by the scientific communities, health officials and government organizations to detect, treat, and prevent viral infection. However, the complicated life cycle and rapid genetic mutations of viruses demand continuous development of novel medicines with high efficacy and safety profiles. Peptides provide a promising outlook as a tool to combat the spread and re-emergence of viral infection. This article provides an overview of five viral infectious diseases with high global prevalence: influenza, chronic hepatitis B, acquired immunodeficiency syndrome, severe acute respiratory syndrome, and coronavirus disease 2019. The current and potential peptide-based therapies, vaccines, and diagnostics for each disease are discussed.